
BioLattice Ophthalmics is developing CorneaClear™, a first-in-class engineered corneal implant for full-thickness cornea replacement. It addresses the global donor shortage and aims to become a new standard of care. CorneaClear™ is compatible with existing surgical procedures and eliminates the immunologic risks associated with donor tissue.
Lead Program & Pipeline
-
Lead product: CorneaClear™ – a bioengineered, full-thickness corneal implant
-
Designed as a scalable, ambient-stable alternative to donor cornea tissue
-
Targets global corneal blindness affecting over 13 million people
-
Enables standard penetrating keratoplasty with no new surgical training required
-
Aims to become the new standard of care for corneal replacement
Technology Differentiators
-
Implanted using standard penetrating keratoplasty techniques — no retraining required
-
Stable at ambient temperature, enabling broad accessibility
-
Eliminates immune rejection risks and donor tissue variability
-
Scalable, GMP-compatible manufacturing process for consistent quality and supply
Stage & Investment
-
Stage: Preclinical
-
Funding Raised: $1.25M oversubscribed pre-seed round (Dec 2024)
-
IP: Provisional patent filed; non-provisional planned for 2025
-
Collaborators: Wills Eye Hospital, Thomas Jefferson University, Lehigh University
What's Next
-
Complete pilot animal studies and FDA pre-submission meeting
-
Initiate GLP studies and prepare 510(k) regulatory strategy
-
Build reimbursement and surgeon education packages
-
Open $2M seed round to support FDA IDE submission and clinical development